Janice Gomes1,2, Fabrice Lucien1,3,4, Tyler T Cooper5, Yohan Kim1,3,4, Karla C Williams3,4, XinYang Liao4, Lauren Kaufman6, Francois Lagugné-Labarthet6, Oliver Kenyon7, Justin Boysen8, Neil E Kay8, Christopher W McIntyre1,2, Hon S Leong1,3,4. 1. Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada. 2. Kidney Clinical Research Unit, London Health Sciences Centre, London, Ontario, Canada. 3. Department of Urology, Mayo Clinic, Rochester, Minnesota, United States. 4. Translational Prostate Cancer Research Laboratory, Lawson Health Research Institute, London, Ontario, Canada. 5. Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada. 6. Department of Chemistry, University of Western Ontario, London, Ontario, Canada. 7. Apogee Flow Systems Inc., Hertfordshire, United Kingdom. 8. Division of Hematology, Mayo Clinic, Rochester, Minnesota, United States.
Abstract
BACKGROUND: Platelet microparticles (PMPs) and their abundance in the blood are a prognostic biomarker in thrombotic disorders and cancer. Nanoscale flow cytometry (nFC) is ideal for high-throughput analysis of PMPs but these clinical assays have not been developed previously. OBJECTIVE: This article demonstrates that nFC is a suitable technology to enumerate PMPs present in plasma samples in a clinical setting. MATERIALS AND METHODS: nFC was performed using the Apogee A50-Micro instrument. Instrument settings and acquisition parameters were developed with the use of fluorescent beads and plasma samples. Sample preparation and handling was also optimized. RESULTS: nFC allows for linear detection of particles between approximately 200 and 1,000 nm based on calibration beads and was dependent on dilution factor and flow rate. Linearity in event analysis as samples became more diluted was lost when events approximately 100 nm were gated while linearity was maintained despite dilution of sample in events larger than 200 nm in diameter. Higher flow rates lead to an under-estimation of events analysed per microlitre of analyte and this was more pronounced when plasma samples were not diluted more than 1/20×. CONCLUSION: nFC offers multi-parametric analysis of PMPs when optimal calibration of acquisition and sample processing settings is performed. Analysis of plasmas from metastatic prostate cancer patients and leukaemia patients revealed that PMP levels were larger than 100 nm and were equally abundant in patients that responded to or failed androgen deprivation therapy or between patients representing different stages of leukaemia. Georg Thieme Verlag KG Stuttgart · New York.
BACKGROUND: Platelet microparticles (PMPs) and their abundance in the blood are a prognostic biomarker in thrombotic disorders and cancer. Nanoscale flow cytometry (nFC) is ideal for high-throughput analysis of PMPs but these clinical assays have not been developed previously. OBJECTIVE: This article demonstrates that nFC is a suitable technology to enumerate PMPs present in plasma samples in a clinical setting. MATERIALS AND METHODS: nFC was performed using the Apogee A50-Micro instrument. Instrument settings and acquisition parameters were developed with the use of fluorescent beads and plasma samples. Sample preparation and handling was also optimized. RESULTS: nFC allows for linear detection of particles between approximately 200 and 1,000 nm based on calibration beads and was dependent on dilution factor and flow rate. Linearity in event analysis as samples became more diluted was lost when events approximately 100 nm were gated while linearity was maintained despite dilution of sample in events larger than 200 nm in diameter. Higher flow rates lead to an under-estimation of events analysed per microlitre of analyte and this was more pronounced when plasma samples were not diluted more than 1/20×. CONCLUSION: nFC offers multi-parametric analysis of PMPs when optimal calibration of acquisition and sample processing settings is performed. Analysis of plasmas from metastatic prostate cancerpatients and leukaemiapatients revealed that PMP levels were larger than 100 nm and were equally abundant in patients that responded to or failed androgen deprivation therapy or between patients representing different stages of leukaemia. Georg Thieme Verlag KG Stuttgart · New York.
Authors: Fabrice Lucien; Eduardo E Benarroch; Aidan Mullan; Farwa Ali; Bradley F Boeve; Michelle M Mielke; Ronald C Petersen; Yohan Kim; Cole Stang; Emanuele Camerucci; Owen A Ross; Zbigniew K Wszolek; David Knopman; James Bower; Wolfgang Singer; Rodolfo Savica Journal: PLoS One Date: 2022-04-08 Impact factor: 3.240
Authors: Benjamin T Himes; Timothy E Peterson; Tristan de Mooij; Luz M Cumba Garcia; Mi-Yeon Jung; Sarah Uhm; David Yan; Jasmine Tyson; Helen J Jin-Lee; Daniel Parney; Yasmina Abukhadra; Michael P Gustafson; Allan B Dietz; Aaron J Johnson; Haidong Dong; Rachel L Maus; Svetomir Markovic; Fabrice Lucien; Ian F Parney Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300
Authors: Jacob J Orme; Khalid A Jazieh; Tiancheng Xie; Susan Harrington; Xin Liu; Matthew Ball; Benjamin Madden; M Cristine Charlesworth; Tariq U Azam; Fabrice Lucien; Bharath Wootla; Yanli Li; Jose Caetano Villasboas; Aaron S Mansfield; Roxana S Dronca; Haidong Dong Journal: Oncoimmunology Date: 2020-04-14 Impact factor: 8.110
Authors: Ashley E Russell; Alexandra Sneider; Kenneth W Witwer; Paolo Bergese; Suvendra N Bhattacharyya; Alexander Cocks; Emanuele Cocucci; Uta Erdbrügger; Juan M Falcon-Perez; David W Freeman; Thomas M Gallagher; Shuaishuai Hu; Yiyao Huang; Steven M Jay; Shin-Ichi Kano; Gregory Lavieu; Aleksandra Leszczynska; Alicia M Llorente; Quan Lu; Vasiliki Mahairaki; Dillon C Muth; Nicole Noren Hooten; Matias Ostrowski; Ilaria Prada; Susmita Sahoo; Tine Hiorth Schøyen; Lifu Sheng; Deanna Tesch; Guillaume Van Niel; Roosmarijn E Vandenbroucke; Frederik J Verweij; Ana V Villar; Marca Wauben; Ann M Wehman; Hang Yin; David Raul Francisco Carter; Pieter Vader Journal: J Extracell Vesicles Date: 2019-11-08
Authors: Hara T Georgatzakou; Efthimia G Pavlou; Effie G Papageorgiou; Issidora S Papassideri; Anastasios G Kriebardis; Marianna H Antonelou Journal: Front Cell Dev Biol Date: 2020-04-15
Authors: Jacob J Orme; Elizabeth Ann L Enninga; Fabrice Lucien-Matteoni; Heather Dale; Edwin Burgstaler; Susan M Harrington; Matthew K Ball; Aaron S Mansfield; Sean S Park; Mathew S Block; Svetomir N Markovic; Yiyi Yan; Haidong Dong; Roxana S Dronca; Jeffrey L Winters Journal: J Immunother Cancer Date: 2020-08 Impact factor: 12.469